At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 301 enrolled
Drug / intervention
NYX-2925 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
In Brief
A Phase 2 clinical trial evaluating NYX-2925 and Placebo for Diabetic Peripheral Neuropathy. Completed, enrolled 301 participants across 35 sites.
Detailed Summary
To evaluate the efficacy of multiple dose levels of NYX-2925 versus placebo in treating the neuropathic pain associated with Diabetic Peripheral Neuropathy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Peripheral Neuropathy
CountriesUnited States
CollaboratorsSyneos Health
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartJun 2017
First PostedJul 2017
Primary CompletionNov 2018
TodayJul 2026
First PostedJul 17, 2017
Enrollment StartJun 27, 2017
Primary CompletionNov 2, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.0 years ago
Interventions
NYX-2925drug
NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
Placebodrug
Matching Placebo capsules.